Bliddal H, Bech K, Kirkegaard C
Horm Metab Res. 1984 Nov;16(11):602-5. doi: 10.1055/s-2007-1014861.
Thyroid stimulating antibodies (TSAb) and thyrotropin binding inhibiting immunoglobulins (TBII) were measured in 32 patients with Graves' disease who had been in remission for at least two years after treatment was been stopped. Seventeen patients had been treated with antithyroid drugs, and 15 patients with 131Iodine. In the first group 3 of 17 patients had TSAb and one TBII, whereas in the second group 4 of 15 patients had TSAb and two TBII. One patient from each group had inhibiting TSAb. During the follow-up one patient from each group relapsed, whereas 5 patients from the second group developed myxoedema. No relationship between the clinical outcome and TSAb and TBII was found.
对32例格雷夫斯病患者进行了甲状腺刺激抗体（TSAb）和促甲状腺素结合抑制性免疫球蛋白（TBII）检测，这些患者在停止治疗后至少已缓解两年。17例患者接受了抗甲状腺药物治疗，15例患者接受了131碘治疗。在第一组17例患者中，3例有TSAb，1例有TBII；而在第二组15例患者中，4例有TSAb，2例有TBII。每组各有1例患者有抑制性TSAb。在随访期间，每组各有1例患者复发，而第二组有5例患者发生了黏液性水肿。未发现临床结局与TSAb和TBII之间存在关联。
